Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IGI

Plasma-derived product · developed by Baxalta now part of Shire

Phase 3 Most advanced trial

TAK Developer

1 Registered trials

What is IGI?

IGI is an intravenous immunoglobulin (IVIG) preparation at 10% concentration. It is studied in multiple myeloma and secondary immunodeficiency.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Plasma-derived product
Therapy area: Oncology
Developer: Baxalta now part of Shire (TAK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06980480	Phase 3	Multiple Myeloma	Recruiting	TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple MyelomaSecondary Immunodeficiency

More from Baxalta now part of Shire

Maribavir FDA approved Susoctocog Alfa FDA approved Vedolizumab FDA approved Vonicog Alfa FDA approved Elritercept Phase 3 GDX012 Phase 1/2 Mezagitamab Phase 3 MNI-792 Phase 1 Pevonedistat Phase 2/3 Soticlestat Phase 3 TAK-186 Phase 1/2 TAK-188 Phase 1/2

Follow TAK, the company behind IGI

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z